Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluating Safety, Efficacy and Pharmacokinetics of a Modified Regimen of Ublituximab (ENHANCE )

NCT05877963 is registered in ClinicalTrials.gov with TG Therapeutics, Inc. as lead sponsor.

NCT NCT05877963
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05877963 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluating Safety, Efficacy and Pharmacokinetics of a Modified Regimen of Ublituximab (ENHANCE )
Lead sponsor
TG Therapeutics, Inc.
Phase
Phase 3
Overall status
Recruiting
Start date
June 13, 2023
Completion date
January 21, 2027
Enrollment
800 (estimated)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing multiple sclerosis